2015
Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non–Small-Cell Lung Cancer
Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, Wilson LD, Decker RH, Yu JB. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2015, 33: 2727-2734. PMID: 26101240, DOI: 10.1200/jco.2015.61.1517.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDatabases, FactualFemaleHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMiddle AgedNeoplasm StagingNeoplasm, ResidualPneumonectomyRadiotherapy DosageRadiotherapy, AdjuvantRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRegistriesRetrospective StudiesTreatment OutcomeUnited StatesConceptsUse of PORTPostoperative radiotherapyOverall survivalNodal stageStage IIMultivariable analysisPatient populationLung cancerNon-small cell lung cancerOverall American Joint CommitteeNational Cancer Data BaseImproved overall survivalLower nodal stagePostoperative radiation therapyPositive surgical marginsAmerican Joint CommitteeCancer stage IICell lung cancerProportional hazards regressionMultivariable logistic regressionClinicopathologic covariatesChemotherapy receiptPerioperative mortalityOnly patientsSuch patients
2014
Poorer Prognosis of African-American Patients With Mycosis Fungoides: An Analysis of the SEER Dataset, 1988 to 2008
Nath SK, Yu JB, Wilson LD. Poorer Prognosis of African-American Patients With Mycosis Fungoides: An Analysis of the SEER Dataset, 1988 to 2008. Clinical Lymphoma Myeloma & Leukemia 2014, 14: 419-423. PMID: 24508350, PMCID: PMC4081527, DOI: 10.1016/j.clml.2013.12.018.Peer-Reviewed Original ResearchConceptsDisease-specific survivalAA raceRT utilizationRadiation therapyOverall survivalTumor stageMultivariate analysisInitial treatment modalityWorse overall survivalAfrican American patientsPublic-use databaseClinical factorsTumor RegistryAA patientsFemale patientsMycosis fungoidesWorse prognosisPoor prognosisFemale sexTreatment modalitiesAdvanced agePoor survivalPoorer PrognosisPatientsMedical care
2008
Advances in Radiotherapy for Lung Cancer
Decker R, Wilson L. Advances in Radiotherapy for Lung Cancer. Seminars In Respiratory And Critical Care Medicine 2008, 29: 285-290. PMID: 18506666, DOI: 10.1055/s-2008-1076748.Peer-Reviewed Original ResearchConceptsLung cancerAggressive local therapyEarly lung tumorsProphylactic cranial irradiationPositron emission tomographic imagingDefinitive treatment optionCell lung cancerRole of radiosurgeryOngoing clinical investigationsEmission tomographic imagingNormal tissue toxicityCranial irradiationPalliative therapyPostoperative radiationLocal therapyLung irradiationAdvanced tumorsTreatment optionsCancer helpLung tumorsRadiation therapyClinical investigationRadiation treatment planningTissue toxicityTherapy
2000
Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides
Wilson L, Jones G, Kim D, Rosenthal D, Christensen I, Edelson R, Heald P, Kacinski B. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. Journal Of The American Academy Of Dermatology 2000, 43: 54-60. PMID: 10863224, DOI: 10.1067/mjd.2000.105510.Peer-Reviewed Original ResearchConceptsTotal skin electron beam radiationCause-specific survivalProgression-free survivalErythrodermic mycosis fungoidesDisease-free survivalExtracorporeal photopheresisPrognosis of patientsMycosis fungoidesOverall survivalTotal skin electron beam therapyComplete response ratePercent of patientsManagement of patientsMonths of completionCancer Care OntarioTreatment 2 daysElectron beam therapyHematologic involvementComplete respondersStage IVAMedian ageCox regressionPatientsTherapeutic RadiologyYale University SchoolPrognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation
Yoo S, Carter D, Turner B, Sasaki C, Son Y, Wilson L, Glazer P, Haffty B. Prognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation. International Journal Of Cancer 2000, 90: 22-28. PMID: 10725854, DOI: 10.1002/(sici)1097-0215(20000220)90:1<22::aid-ijc3>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsEarly-stage larynx cancerLocal relapsePrognostic significanceLarynx cancerTotal median dosePrimary radiation therapySquamous cell carcinomaCell nuclear antigen levelsParaffin-embedded specimensSignificant clinical implicationsCase-control designPercent distributionLarynx cancer patientsCyclin D1 protein levelsCyclin D1 levelsMedian doseControl patientsLocal recurrenceAntigen levelsCancer patientsCell carcinomaDaily fractionsRadiation therapyIndex caseClinical informationPSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients
Peschel R, Robnett T, Hesse D, King C, Ennis R, Schiff P, Wilson L. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. International Journal Of Cancer 2000, 90: 29-36. PMID: 10725855, DOI: 10.1002/(sici)1097-0215(20000220)90:1<29::aid-ijc4>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsPostoperative radiation therapyBNED survival ratesAdjuvant radiation therapyHigh-risk patientsSalvage radiation therapyPostoperative prostate cancer patientsProstate cancer patientsRadiation therapySurvival ratePSA levelsBiochemical failureCancer patientsBiochemical disease-free survival ratesHigh-risk surgery patientsDisease-free survival ratesAdjuvant radiation groupPreoperative PSA levelSeminal vesicle involvementEarly prostate cancerLife table methodAdjuvant settingSalvage radiationClinical recurrenceSurgery patientsClinical factors
1999
The changing survival of patients with mycosis fungoides
Jones G, Wilson L. The changing survival of patients with mycosis fungoides. Cancer 1999, 86: 191-193. PMID: 10391580, DOI: 10.1002/(sici)1097-0142(19990701)86:1<191::aid-cncr26>3.0.co;2-e.Peer-Reviewed Original ResearchTotal skin electron radiation for patients with erythrodermic cutaneous T‐cell lymphoma (mycosis fungoides and the Sézary syndrome)
Jones G, Rosenthal D, Wilson L. Total skin electron radiation for patients with erythrodermic cutaneous T‐cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 1999, 85: 1985-1995. PMID: 10223240, DOI: 10.1002/(sici)1097-0142(19990501)85:9<1985::aid-cncr16>3.0.co;2-o.Peer-Reviewed Original ResearchConceptsErythrodermic mycosis fungoidesBlood involvementMycosis fungoidesCutaneous remissionSpecific survivalStage IIIErythrodermic cutaneous T-cell lymphomaTotal skin electron beam radiationMedian cause-specific survivalCutaneous T-cell lymphomaMedian overall survivalStage IVB diseaseCause-specific survivalStage III diseaseMedian radiation doseMedian treatment timeT-cell lymphomaToxicity of radiationIVB diseaseAdjuvant therapyStage IVAVisceral involvementModality therapyOverall survivalLymph nodesEvaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides).
Thayu M, Tallini G, Glusac E, Kacinski B, Wilson L. Evaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides). The Yale Journal Of Biology And Medicine 1999, 72: 365-75. PMID: 11138932, PMCID: PMC2579043.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free intervalMycosis fungoidesPolymerase chain reactionSkin biopsiesMedian disease-free intervalCutaneous T-cell lymphomaT-cell receptor gene rearrangementsDominant TCR clonesT-cell receptor gamma gene rearrangementEvaluation of patientsTissue samplesIdentification of patientsT-cell lymphomaGene rearrangementsReceptor gene rearrangementsGamma gene rearrangementsRecurrent mycosis fungoidesElectron beam therapyDominant TCRMF patientsTCR analysisTCR clonesMalignant lymphocytesT lymphocytes
1998
Intraoperative brachytherapy, laryngopharyngoesophagectomy, and gastric transposition for patients with recurrent hypopharyngeal and cervical esophageal carcinoma
Wilson L, Chung J, Haffty B, Cahow E, Sasaki C, Son Y. Intraoperative brachytherapy, laryngopharyngoesophagectomy, and gastric transposition for patients with recurrent hypopharyngeal and cervical esophageal carcinoma. The Laryngoscope 1998, 108: 1504-1508. PMID: 9778290, DOI: 10.1097/00005537-199810000-00014.Peer-Reviewed Original ResearchConceptsExternal beam radiationGastric transpositionCervical esophagusLocal controlMedian doseRecurrent carcinomaActuarial local controlCervical esophageal carcinomaLymphvascular space invasionTotal median doseLymph node dissectionGood local controlAcceptable risk profileActuarial survivalNode dissectionFacial painNodal involvementOverall survivalRecurrent diseaseCervical abscessIntraoperative brachytherapyMale patientsMedian ageMucosal hemorrhageFacial edemaEffective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy
Turner B, Knisely J, Kacinski B, Haffty B, Gumbs A, Roberts K, Frank A, Peschel R, Rutherford T, Edraki B, Kohorn E, Chambers S, Schwartz P, Wilson L. Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 77-84. PMID: 9422561, DOI: 10.1016/s0360-3016(97)00581-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyChemotherapy, AdjuvantCystadenocarcinoma, PapillaryDisease-Free SurvivalFemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesSalvage TherapyUterine NeoplasmsConceptsUterine papillary serous carcinomaWhole pelvic radiation therapyWhole-abdomen radiation therapyComplete surgical stagingDisease-free survivalActuarial disease-free survivalFIGO stage IPapillary serous carcinomaSurgical stagingActuarial OSOverall survivalSalvage rateStage IRadiation therapyUPSC patientsVaginal brachytherapyMyometrial invasionSerous carcinomaLDR brachytherapyRadiation Therapy Oncology Group (RTOG) grade 1DFS of patientsPara-aortic lymph node samplingConventional external beam radiotherapyFIGO stage IARTOG grade 3Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Wilson L, Kacinski B, Jones G. Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides). International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 109-115. PMID: 9422565, DOI: 10.1016/s0360-3016(97)00553-1.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaStage IA mycosis fungoidesT-cell lymphomaAdjuvant therapyLocal controlMycosis fungoidesSuperficial radiationSuperficial radiotherapyDistant skin sitesMedian fraction numberMedian surface doseComplete response rateExcellent local controlDry desquamationPrior therapyHematologic toxicityPrior radiationDistant failurePersistent diseaseMedian ageCutaneous malignanciesPathologic documentationSurface doseMild erythemaPatients
1997
Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)
Quirós P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, Wilson L. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). International Journal Of Radiation Oncology • Biology • Physics 1997, 38: 1027-1035. PMID: 9276369, DOI: 10.1016/s0360-3016(97)00127-2.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free survivalT2 patientsCrude relapse rateAdjuvant therapyOverall survivalElectron beam therapyRelapse rateEntire cohortMedian disease-free survivalCutaneous T-cell lymphomaBeam therapySalvage of recurrencesAdjuvant systemic therapyEarly-stage patientsManagement of patientsT-cell lymphomaTopical nitrogen mustardDays/weekCombination of therapiesGy/dayTreatments/weekPUVA patientsMedian followSalvage therapyMycosis Fungoides and Total Skin Electron Beam Radiation
Jones G, Wilson L, Kurzrock R, Diamandidou E, >Ha C, Cohen P. Mycosis Fungoides and Total Skin Electron Beam Radiation. Blood 1997, 89: 3062-3064. PMID: 9108429, DOI: 10.1182/blood.v89.8.3062.Peer-Reviewed Original ResearchTreatment of recurrent pelvic and selected primary gynecologic malignancies with 241Am
Chung J, Roberts K, Peschel R, Nath R, Pourang R, Kacinski B, Wilson L. Treatment of recurrent pelvic and selected primary gynecologic malignancies with 241Am. International Journal Of Cancer 1997, 5: 227-234. PMID: 9372545, DOI: 10.1002/(sici)1520-6823(1997)5:5<227::aid-roi3>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsRecurrent pelvic malignanciesPrimary gynecologic malignanciesPrimary radiotherapySurgical salvageMicroscopic diseasePelvic malignanciesPostoperative radiotherapyGynecologic malignanciesUltimate local control rateExternal beam radiation therapyGross primary tumorMedian patient ageLocal control rateTreatment of recurrentBeam radiation therapyMicroscopic residuumTreatment intentPatient ageSurgical resectionCurative therapyGynecologic tumorsGynecologic cancerControl ratePrimary tumorRadiation therapyBioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
Haffty B, Son Y, Wilson L, Papac R, Fischer D, Rockwell S, Sartorelli A, Ross D, Sasaki C, Fischer J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. International Journal Of Cancer 1997, 5: 235-245. PMID: 9372546, DOI: 10.1002/(sici)1520-6823(1997)5:5<235::aid-roi4>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaWhite blood cell countPhase I trialCell carcinomaRadiation therapyMitomycin CNonhematological toxicitiesI trialStage III/IV squamous cell carcinomaCourse of RTTotal median doseAcceptable toxicity profilePhase III trialsCurrent ongoing trialsDisease survival ratesDaily radiation therapyBlood cell countHypoxic cell cytotoxinActuarial survivalHemoglobin nadirsAdvanced diseaseMedian doseIII trialsOngoing trialsMultiinstitutional trial
1996
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 1996, 35: 69-73. PMID: 8682967, DOI: 10.1016/s0190-9622(96)90499-5.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaComplete responseT-cell lymphomaElectron beam therapySecond courseMedian disease-free intervalThird courseAdditional coursesBeam therapyDisease-free intervalTreatment of patientsAcceptable risk profileForm of therapyMedian doseMedian survivalMild erythemaPatientsInitial courseTherapyVariety of modalitiesRisk profileEntire groupLocalized radiationExtent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy
Quiros P, Kacinski B, Wilson L. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996, 77: 1912-1917. PMID: 8646693, DOI: 10.1002/(sici)1097-0142(19960501)77:9<1912::aid-cncr23>3.0.co;2-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBody Surface AreaChemotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy DosageRadiotherapy, High-EnergyRemission InductionRetrospective StudiesSkinSkin NeoplasmsSurvival RateConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaComplete clinical responseOverall survivalSkin involvementT-cell lymphomaMedian DFSPrognostic indicatorTotal skin electron beam radiation therapyToxicity of therapyElectron beam radiation therapyBeam radiation therapyTotal skin surfaceElectron beam therapyFree survivalClinical responsePrognostic significanceTumor nodulesRadiation therapyPatientsPatient recordsTherapyDiseaseBeam therapyMonths
1995
Subareolar breast cancer: Long-term results with conservative surgery and radiation therapy
Haffty B, Wilson L, Smith R, Fischer D, Beinfield M, Ward B, McKhann C. Subareolar breast cancer: Long-term results with conservative surgery and radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 1995, 33: 53-57. PMID: 7642431, DOI: 10.1016/0360-3016(95)00165-u.Peer-Reviewed Original ResearchConceptsEntire nipple areolar complexSubareolar breast cancersNipple-areolar complexEarly-stage breast cancerMajority of patientsStage breast cancerAreolar complexBreast cancerConservative surgeryRadiation therapyMedian doseConservative managementRelative contraindicationAxillary lymph node dissectionDistant disease-free survivalYale-New Haven HospitalTotal median doseAdjuvant systemic therapyLymph node dissectionRegional nodal irradiationDisease-free survivalRecurrence-free survivalSubset of patientsTime of surgeryLong-term resultsSystemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy
Wilson L, Licata A, Braverman I, Edelson R, Heald P, Feldman A, Kacinski B. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1995, 32: 987-995. PMID: 7607973, DOI: 10.1016/0360-3016(95)00073-8.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDoxorubicin/cyclophosphamideCutaneous T-cell lymphoma patientsAdjuvant doxorubicin/cyclophosphamideT-cell lymphoma patientsExtracorporeal photochemotherapyComplete responseOverall survivalAdjuvant therapyElectron beam therapyAdjuvant regimenFree survivalCTCL patientsLymphoma patientsBeam therapyAddition of chemotherapyAdvanced stage CTCLClinical complete responseSystemic adjuvant therapyGood partial responseSignificant survival benefitBetter overall survivalRelapse-free survivalSoles of feetNontoxic regimen